Research Paper Volume 12, Issue 2 pp 1285—1303

DNAH10 mutation correlates with cisplatin sensitivity and tumor mutation burden in small-cell lung cancer

Figure 7. (A) Distribution of TMB based on the DNAH10 mutation status of 55 SCLC cell lines in the GDSC database. (B) Correlation between TMB and WES and ln IC50 values of 55 SCLC cell lines in GDSC (P = 0.0166; Sprearman r = 0.3247). (C) Trend toward increased mutational counts in DDR-related pathway in patients with DNAH10 mutation. (D) Distribution of DNAH10 expression based on DNAH10 mutation status of 55 SCLC cell lines in the GDSC database. (E) Trend toward increased immune checkpoint expression in patients with DNAH10 mutation. SCLC: Small-cell lung cancer; GDSC: The Genomics of Drug Sensitivity in Cancer Project; (F) ln IC50 values of three drugs based on DNAH10 mutation status of SCLC cell lines in GDSC. SCLC: Small-cell lung cancer; GDSC: The Genomics of Drug Sensitivity in Cancer Project; FA, Fanconi anemia; HR, homologous recombination; NHEJ, non-homologous end joining; BER, base excision repair; MMR, mismatch repair; NER, nucleotide excision repair; DSB, double strand breaks; SSB, single strand breaks; TMB, tumor mutational burden.